. Author manuscript; available in PMC: 2013 Jul 15.

Published in final edited form as: Curr Pharm Des. 2013;19(10):1880–1897. doi: 10.2174/1381612811319100011

Table 4.

Anti-HIV-1 activity of 4′-ethynylstavudine^a

Compound	Virus	Cells	EC₅₀^b (μM)	CC₅₀^c (μM)
4′-Ed4T	III_B	MT-2	0.25 ± 0.14	> 100
		MT-4	0.07 ± 0.041	> 100
		PBMC	0.0019 ± 0.0002	56 ± 3
	Ba-L	PBMC	0.0076 ± 0.0013
d4T	III_B	MT-2	1.3 ± 0.4	98 ± 11
		MT-4	0.31 ± 0.07	79 ± 19
		PBMC	0.019 ± 0.004	28 ± 7
	Ba-L	PBMC	0.047 ± 0.027
3TC	III_B	MT-4	0.60 ± 0.03	> 100

Data from reference 34 and 35

50% Effective concentration

50% Cytotoxic concentration